Neoplasm

In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups

Retrieved on: 
Thursday, March 7, 2024

“Incorporating DecisionDx-SCC test results into the management of high-risk SCC can help ensure patients receive the best care possible by incorporating their biological risk of metastasis into the treatment plan.

Key Points: 
  • “Incorporating DecisionDx-SCC test results into the management of high-risk SCC can help ensure patients receive the best care possible by incorporating their biological risk of metastasis into the treatment plan.
  • DecisionDx-SCC also provided significant and clinically actionable risk stratification in various patient subgroups, including NCCN high and very high-risk, lower-stage BWH tumors and Medicare-eligible patients, further stratifying risk to help guide important treatment decisions for these patients.
  • These data support the use of DecisionDx-SCC test results, informed by a patient’s tumor biology, to guide personalized patient treatment decisions aligned to a patient’s risk of metastasis over three years.
  • “As such, we continue to develop evidence showing that our test adds independent prognostic value to the clinical and pathologic risk factors used for guiding risk-informed treatment plans within current guidelines.

Apollo Hospital in New Delhi Initiates First Non-Invasive ZAP-X Brain Tumor Treatment in South Asia

Retrieved on: 
Thursday, March 7, 2024

ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that Apollo Hospital in New Delhi, India, completed its first patient treatment using the new ZAP-X® Gyroscopic Radiosurgery® platform.

Key Points: 
  • ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that Apollo Hospital in New Delhi, India, completed its first patient treatment using the new ZAP-X® Gyroscopic Radiosurgery® platform.
  • This pioneering approach aims to maximally safeguard healthy brain tissue and preserve patient cognitive function.
  • “Pineal tumors are extremely difficult to remove with open surgery as they are anatomically located within the center of the brain.
  • “ZAP is honored to support Apollo Hospitals in expanding global access to this potentially life-saving treatment.”

City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial

Retrieved on: 
Thursday, March 7, 2024

One of the main challenges for treating brain cancer is that medications have difficulty crossing the blood-brain barrier.

Key Points: 
  • One of the main challenges for treating brain cancer is that medications have difficulty crossing the blood-brain barrier.
  • Twenty-nine of the 58 patients with recurrent high-grade glioma brain tumors, mostly glioblastoma, achieved stable disease after treatment with CAR T cells for at least two months.
  • There were two partial responses, one complete response and a second complete response after additional CAR T cell therapy cycles were delivered under compassionate use.
  • The study team also included researchers from Translational Genomics Research Institute in Phoenix, which is part of City of Hope.

Montdorex Announces Acceptance of Its Abstract for Presentation at the AACR Annual Meeting 2024

Retrieved on: 
Thursday, March 7, 2024

The endo-exonuclease enzyme plays a key role in DNA damage repair mechanisms, but it is also overexpressed in cancer tumors.

Key Points: 
  • The endo-exonuclease enzyme plays a key role in DNA damage repair mechanisms, but it is also overexpressed in cancer tumors.
  • In a proof-of-concept study, Montdorex showed that tumors with increased EE expression showed the best response to pentamidine, an endo-exonuclease inhibitor.
  • “Our lead candidate, MTDX203, showed an increased anti-cancer activity with a higher safety index than pentamidine in preclinical animal studies,” said Terry Chow of Montdorex.
  • “I look forward to presenting our detailed findings to the AACR scientific and investor community at the upcoming annual meeting.”
    Details of the AACR poster presentation are as follows:
    Poster Presentation (#5604): Modulating DNA repair through endo-exonuclease inhibition: a new therapeutic paradigm in Oncology [ link to the abstract ]

TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101

Retrieved on: 
Thursday, March 7, 2024

“The WHO INN and USAN approval of nelitolimod is an important milestone in the continued progress we are making with our nelitolimod program,” said Mary Szela, Chief Executive Officer and President of TriSalus.

Key Points: 
  • “The WHO INN and USAN approval of nelitolimod is an important milestone in the continued progress we are making with our nelitolimod program,” said Mary Szela, Chief Executive Officer and President of TriSalus.
  • This approach has the potential to enable more durable responses by patients to other immunotherapeutics, thereby facilitating better patient outcomes.
  • Information on nelitolimod will be posted on the USAN website ( www.ama-assn.org/go/usan ) and will be published in the Chemical Abstracts Service and in the U.S. Pharmacopeia.
  • Going forward, TriSalus will use the name in publications and public statements, at conferences and other forums, and in corporate-related materials.

Non-Small-Cell Lung Cancer (NSCLC) Pipeline Landscape Report 2024: Comprehensive Insights About 100+ Companies and 120+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 6, 2024

This report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape.
  • A detailed picture of the Non-Small-Cell Lung cancer (NSCLC) pipeline landscape is provided which includes the disease overview and Non-Small-Cell Lung cancer (NSCLC) treatment guidelines.
  • The assessment part of the report embraces, in depth Non-Small-Cell Lung cancer (NSCLC) commercial assessment and clinical assessment of the pipeline products under development.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Non-Small-Cell Lung cancer (NSCLC) R&D.

Sporos BioDiscovery to Present Preclinical Findings on SPR1, a Next-Generation TEAD Inhibitor, at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Wednesday, March 6, 2024

Sporos BioDiscovery, Inc. (a portfolio company of Sporos Bioventures, LLC.

Key Points: 
  • Sporos BioDiscovery, Inc. (a portfolio company of Sporos Bioventures, LLC.
  • ), a precision oncology company developing a diversified pipeline of small molecule therapeutic programs targeting cancer vulnerabilities in the tumor and tumor microenvironment, today announced that it will present two posters highlighting preclinical data from the company’s novel TEAD1 / TEAD4 isoform selective inhibitor, SPR1, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, CA.
  • “We look forward to presenting two posters at this year’s AACR meeting that highlight the significant preclinical work we have done to characterize SPR1 as a potential best-in-class TEAD inhibitor.
  • In addition, our team’s expert biological analysis has uncovered a new therapeutic vulnerability that could broaden the potential use of SPR1, a TEAD1/4 inhibitor, to a new subset of cancers with certain homozygous deletions,” said Stephen Rubino, Ph.D., President of Sporos BioDiscovery.

Foundation Medicine Announces Details of Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024

Foundation Medicine, Inc ., a genomics company dedicated to transforming cancer care, today announced that research from its robust oncology diagnostics portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California April 5-10, 2024.

Key Points: 
  • Foundation Medicine, Inc ., a genomics company dedicated to transforming cancer care, today announced that research from its robust oncology diagnostics portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California April 5-10, 2024.
  • ​Results suggest ​serial early ctDNA monitoring ​is a valuable complementary tool for real-time treatment response monitoring to targeted therapy.
  • These findings may enable personalized therapy approaches tailored to a patient’s risk of progression and downstream cancer treatment planning.
  • Follow Foundation Medicine on LinkedIn and X for more updates from #AACR24 and visit us in person at booth #3117.

Cancer Grand Challenges announces five new teams taking on cancer’s toughest challenges

Retrieved on: 
Wednesday, March 6, 2024

Cancer Grand Challenges, a global research funding initiative co-founded by Cancer Research UK and the National Cancer Institute, today announces funding for five new global research teams to take on some of the toughest cancer challenges: cancer inequities, early-onset cancers, solid tumors in children and T-cell receptors.

Key Points: 
  • Cancer Grand Challenges, a global research funding initiative co-founded by Cancer Research UK and the National Cancer Institute, today announces funding for five new global research teams to take on some of the toughest cancer challenges: cancer inequities, early-onset cancers, solid tumors in children and T-cell receptors.
  • These include the Scientific Foundation of the Spanish Association Against Cancer, the Bowelbabe Fund for Cancer Research UK, Institut National Du Cancer, the Dutch Cancer Society, The Mark Foundation for Cancer Research and KiKa (Children Cancer Free Foundation).
  • “Together with our network of visionary partners and research leaders, Cancer Grand Challenges unites the world's brightest minds across boundaries and disciplines and aims to overcome cancer’s toughest problems,” said Dr. David Scott, Director of Cancer Grand Challenges.
  • The Cancer Grand Challenges community has grown to more than 1,200 investigators and collaborators with 16 teams from across the world taking on 13 challenges.

Ankyra Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Dose Escalation Cohort Evaluating ANK-101, an Anchored Immune Medicine, for Solid Tumors

Retrieved on: 
Tuesday, March 5, 2024

Ankyra Therapeutics, a clinical stage biotechnology company pioneering anchored immunotherapies to treat cancer, today announced the first patient dosed in the dose escalation cohort in a Phase 1 clinical study evaluating ANK-101, a tumor-directed, anchored immune medicine for solid tumors.

Key Points: 
  • Ankyra Therapeutics, a clinical stage biotechnology company pioneering anchored immunotherapies to treat cancer, today announced the first patient dosed in the dose escalation cohort in a Phase 1 clinical study evaluating ANK-101, a tumor-directed, anchored immune medicine for solid tumors.
  • ANK-101 is currently under investigation in patients with advanced solid tumors who have failed standard of care treatments.
  • In multiple preclinical models, ANK-101 demonstrated increased immune cell infiltration into tumors without systemic toxicity.
  • “These data will provide a roadmap for advancing ANK-101 through clinical development and for identifying appropriate clinical indications for future trials,” said Joe Elassal, M.D., MBA, Chief Medical Officer of Ankyra Therapeutics.